Sarah Crunkhorn
Sarah Crunkhorn
Alex Eccleston
Alex Eccleston
Asher Mullard
Asher Mullard
Frank W Pun,Dmitriy Podolskiy,Evgeny Izumchenko et al.
Frank W Pun et al.
Drug discovery and development is time-intensive, expensive and laden with risk. Identifying the right drug targets is crucial for increasing the probability of success, but traditional target identification and validation often take years,...
Safety considerations for cereblon-recruiting targeted protein degraders [0.03%]
招募Cereblon降解靶点蛋白的安全性考虑因素
Helen Garside,Amy Aslamkhan,Danette L Daniels et al.
Helen Garside et al.
Targeted protein degraders (TPDs) that recruit the E3 ligase cereblon (CRBN) include two innovative drug classes: molecular glue degraders and proteolysis targeting chimeras. These TPDs have shown great promise in addressing difficult drug ...
Realizing the promise of CAR-T cell therapies for autoimmune diseases [0.03%]
实现CAR-T细胞疗法治疗自身免疫性疾病的潜力
Gwendolyn K Binder,Raphaël Ognar
Gwendolyn K Binder
Paul Verdin
Paul Verdin
Asher Mullard
Asher Mullard
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics [0.03%]
突破生物学障碍：基于RNA的复杂生物制品非临床安全考量
Sheroy Minocherhomji,Katie Sokolowski,Kelle Franklin et al.
Sheroy Minocherhomji et al.
Alex Eccleston
Alex Eccleston